Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LongShengZhi (LSZ) is a traditional Chinese medicine capsule approved in China for the treatment of ischemic stroke and other cerebrovascular diseases. It is an optimized herbal formulation based on the classical Buyang Huanwu decoction and contains 12 natural medicines with 19 main active ingredients. LSZ exerts neuroprotective, anti-inflammatory, antioxidative, and anti-apoptotic effects. Mechanistically, it downregulates matrix metalloproteinase 2/9 (MMP-2/9), vascular endothelial growth factor (VEGF), and nuclear factor kappa-B (NF-κB), while upregulating microtubule-associated protein-2 (MAP-2) and growth-associated protein-43 (GAP-43). These actions are mediated via p38 MAPK and HIF-1α signaling pathways. LSZ has demonstrated efficacy in improving neurological outcomes after ischemic stroke in both animal models and clinical studies; it also shows potential benefits in Alzheimer-like pathology by reducing oxidative stress, inflammation, neuronal apoptosis, β-secretase activity, γ-secretase subunit expression, PSEN1 expression, and amyloid-beta accumulation[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LongShengZhi.